Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Gedatolisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Celcuity Plans Phase 3 Gedatolisib Trial Secures 62M Debt Financing
    Celcuity Plans Phase 3 Gedatolisib Trial Secures 62M Debt Financing

    30 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/30/2890595/0/en/Celcuity-Inc-Announces-Plan-to-Initiate-a-Phase-3-Clinical-Trial-for-Gedatolisib-as-First-Line-Treatment-for-HR-HER2-Advanced-Breast-Cancer-and-Secures-Approximately-62-Million-Deb.html

    GLOBENEWSWIRE
    30 May 2024
    Share Share
    Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
    Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/27/2853589/0/en/Celcuity-Inc-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 of Gedatolisib
    Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 of Gedatolisib

    22 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/22/2834087/0/en/Celcuity-Announces-First-Patient-Dosed-in-Phase-1b-2-CELC-G-201-Clinical-Trial-of-Gedatolisib-for-the-Treatment-of-Metastatic-Castration-Resistant-Prostate-Cancer.html

    GLOBENEWSWIRE
    22 Feb 2024
    Share Share
    Celcuity Presents Data on Therapeutic Effects of Gedatolisib in Breast Cancer
    Celcuity Presents Data on Therapeutic Effects of Gedatolisib in Breast Cancer

    06 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/12/06/2791761/0/en/Celcuity-Presents-Preclinical-Data-on-Therapeutic-Effects-of-Gedatolisib-in-Breast-Cancer-Models-at-the-2023-San-Antonio-Breast-Cancer-Symposium.html

    GLOBENEWSWIRE
    06 Dec 2023
    Share Share
    Celcuity to Present Preclinical Data for Gedatolisib
    Celcuity to Present Preclinical Data for Gedatolisib

    01 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/01/2789413/0/en/Celcuity-to-Present-Preclinical-Data-for-Gedatolisib-at-the-2023-San-Antonio-Breast-Cancer-Symposium.html

    GLOBENEWSWIRE
    01 Dec 2023
    Share Share
    Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib
    Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib

    09 Dec 2022

    // ACCESSWIRE

    https://www.accesswire.com/731101/Celcuity-Presents-Updated-Results-of-Phase-1b-Study-of-Gedatolisib-in-Patients-with-Advanced-Breast-Cancer-at-the-2022-San-Antonio-Breast-Cancer-Symposium

    ACCESSWIRE
    09 Dec 2022
    Share Share